鉴定和验证5种新型蛋白质点,用于2型糖尿病
Mengjun Tao1, Wufei Ye1, Yang Wu1
1Yijishan Hospital, Wannan Medical College, No. 2 Zheshan West Road, Wuhu, 241001, China.
Scientific reports
|April 9, 2025
概括
这项研究确定了六个与2型糖尿病 (T2DM) 风险相关的基因. CLSTN1,KCNJ11和MLX可能具有保护作用,而RELA和ULK1与增加T2DM风险有关,表明新的治疗点.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 治疗面临挑战,因为缺乏新的治疗点.
- 识别影响T2DM病变的遗传因素对于开发新疗法至关重要.
研究的目的:
- 通过大规模遗传分析,识别与T2DM相关的新型蛋白质编码基因.
- 探索这些基因作为T2DM治疗点的潜力.
主要方法:
- 门德尔的随机化分析将cis表达量化特征位置 (eQTLGen) 数据与T2DM GWAS总结统计数据集成在一起.
- 局部化分析以确定基因表达和T2DM之间的共同因果变异.
- 病例控制研究,以验证T2DM患者中确定的基因关联.
主要成果:
- 42个基因与T2DM有显著的关联.
- 六个基因 (CLSTN1,KCNJ11,MLX,DLD,RELA,ULK1) 显示了与T2DM的共同因果变异.
- CLSTN1,KCNJ11和MLX与T2DM风险有负相关性,而DLD,RELA和ULK1与T2DM风险有积极相关性.
- 在T2DM患者中,验证研究证实了CLSTN1,KCNJ11,MLX的下调和RELA,ULK1的上调.
结论:
- 这些已识别的基因,特别是CLSTN1,KCNJ11,MLX,RELA和ULK1,代表了T2DM的潜在新药标.
- 需要进一步的临床研究来证实这些蛋白标的治疗相关性.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Pathophysiology of Diabetes
820
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
820
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Diabetes: Symptoms, Diagnosis, and Complications
487
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
487
Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139


